Judith G. Deal

机构：Pfizer (United States), Université Bourgogne Franche-Comté

发表论文 17 篇 · 总被引 1300 次 · h-index 10

代表论文

• Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations (2014 · Journal of Medicinal Chemistry · 被引 593)
• Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones (1993 · Journal of Medicinal Chemistry · 被引 162)
• Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib (2014 · Journal of Medicinal Chemistry · 被引 118)
• Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase (1992 · Journal of Medicinal Chemistry · 被引 116)
• Discovery of N -((3 R ,4 R )-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H -pyrazol-4-yl)amino)-9-methyl-9 H -purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR (2017 · Journal of Medicinal Chemistry · 被引 91)
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety (2025 · Cancer Cell · 被引 61)